14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of XERS
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Friday for Xeris Pharmaceuticals Inc stock after gaining 1.61%
(Updated on May 03, 2024)

Hold candidate since May 02, 2024 Gain 1.61% PDF

The Xeris Pharmaceuticals Inc stock price gained 1.61% on the last trading day (Friday, 3rd May 2024), rising from $1.86 to $1.89. During the last trading day the stock fluctuated 4.89% from a day low at $1.84 to a day high of $1.93. The price has risen in 4 of the last 10 days and is up by 8.62% over the past 2 weeks. Volume fell on the last day by -59 thousand shares and in total, 1 million shares were bought and sold for approximately $2.11 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies the upper part of a wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $1.93 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -43.83% during the next 3 months and, with a 90% probability hold a price between $0.87 and $1.08 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

XERS Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, April 25, 2024, and so far it has risen 11.18%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Xeris Pharmaceuticals Inc stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $1.95. On a fall, the stock will find some support from the short-term average at $1.78. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Support, Risk & Stop-loss for Xeris Pharmaceuticals Inc stock

On the downside, the stock finds support just below today's level from accumulated volume at $1.78 and $1.75. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Xeris Pharmaceuticals Inc finds support just below today's level at $1.78. If this is broken, then the next support from accumulated volume will be at $1.75 and $1.74.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.0900 between high and low, or 4.89%. For the last week, the stock has had daily average volatility of 5.37%.

Our recommended stop-loss: $1.83 (-3.40%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 6 days ago.)

Trading Expectations (XERS) For The Upcoming Trading Day Of Monday 6th

For the upcoming trading day on Monday, 6th we expect Xeris Pharmaceuticals Inc to open at $1.89, and during the day (based on 14 day Average True Range), to move between $1.79 and $1.99, which gives a possible trading interval of +/-$0.102 (+/-5.41%) up or down from last closing price. If Xeris Pharmaceuticals Inc takes out the full calculated possible swing range there will be an estimated 10.81% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.78 (5.82%) than the resistance at $2.13 (12.70%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Earnings coming up

Xeris Pharmaceuticals Inc will release earnings BMO on Thursday, May 09, 2024.The consensus among the analysts for the expected earnings (EPS) is -$0.120. We will update the financials statements for Xeris Pharmaceuticals Inc, that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 16.80% in the first trading day after earnings release.

Is Xeris Pharmaceuticals Inc stock A Buy?

Xeris Pharmaceuticals Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Current score: 0.189 Hold/Accumulate Unchanged

Predicted Opening Price for Xeris Pharmaceuticals Inc of Monday, May 6, 2024

Fair opening price May 6, 2024 Current price
$1.89 ( 0.176%) $1.89

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for XERS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.98 4.59 %
R2 1.94 2.77 %
R1 1.92 1.64 %
Current price: 1.89
Support S1 1.85 -2.00 %
S2 1.83 -3.12 %
S3 1.80 -4.94 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.23 17.99 %
R2 2.21 16.93 %
R1 2.13 12.70 %
Current price 1.89
Support S1 1.78 -5.82%
S2 1.75 -7.41%
S3 1.74 -7.94%

FAQ

What is the symbol for Xeris Pharmaceuticals Inc Stock and on which exchange is it traded?
The symbol for Xeris Pharmaceuticals Inc is XERS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Xeris Pharmaceuticals Inc Stock?
Xeris Pharmaceuticals Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Xeris Pharmaceuticals Inc Stock?
Xeris Pharmaceuticals Inc Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Xeris Pharmaceuticals Inc Stock.

What's the current price of Xeris Pharmaceuticals Inc Stock?
As of the end of day on the May 03, 2024, the price of an Xeris Pharmaceuticals Inc (XERS) share was $1.89.

What is the 52-week high and low for Xeris Pharmaceuticals Inc Stock?
The 52-week high for Xeris Pharmaceuticals Inc Stock is $0.0040 and the 52-week low is $0.0030.

What is the market capitalization of Xeris Pharmaceuticals Inc Stock?
As of the May 03, 2024, the market capitalization of Xeris Pharmaceuticals Inc is 280.2M.

When is the next earnings date for Xeris Pharmaceuticals Inc?
The upcoming earnings date for Xeris Pharmaceuticals Inc is May 09, 2024.
Click to get the best stock tips daily for free!

About Xeris Pharmaceuticals Inc

Xeris Pharmaceuticals Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi... XERS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT